The medical device firm forecasts 2026 revenue growth as Q2 2026 sales rise 9% year-over-year to $41.6 million.
Neuronetics set a 2026 revenue target of $160 million to $164 million, signaling confidence in its growth trajectory. The company also announced plans to expand NeuroStar’s ownership models, aiming to broaden market access for its neurostimulation devices.
In Q2 2026, Neuronetics reported $41.6 million in revenue, a 9% increase from the same period last year. The growth reflects steady execution of its strategic goals, according to management during the earnings call.
The company did not disclose immediate market reactions, but the revenue guidance and operational shift may influence investor sentiment in the medtech sector.